The FDA criticized Hims & Hers' Super Bowl ad for weight-loss drugs, saying it broke federal law by showing only benefits, not risks. The agency is now boosting enforcement on misleading drug ads, especially for online pharmacies and compounded drugs.
Hims & Hers launched affordable, personalized low T treatments to boost energy & sexual health. They offer enclomiphene now, and in 2026, will add FDA-approved oral KYZATREX through a partnership with Marius Pharmaceuticals, plus injectables. Patients start with at-home blood tests.
GoodRx partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month to self-paying patients, expanding access for those without adequate insurance. This makes them available at over 70,000 U.S. pharmacies. Hims & Hers down.
Hims & Hers' Q2 profit surged to $42.5M, fueled by 31% subscriber growth (2.4M total). Revenue of $544.8M missed estimates, impacted by wholesale weakness, causing shares to fall. Full-year guidance maintained.
